Community Update: New Insights into Health and Prevention in Angelman Syndrome
A newly published study explores mortality risks in Angelman syndrome, highlighting key preventive areas like silent aspiration and pneumonia, while providing essential care resources for families.
The Economic Burden of Caring for Individuals with Angelman Syndrome
Angelman syndrome affects entire families: a new study estimates caregiving costs nearly $80,000 per household each year, underscoring the urgent need for stronger supports, services, and meaningful treatments.
CAN Spotlight: Matthew Gocker continues to support AS Family in Wisconsin!
One community advocate, one unforgettable night, and $3,000 raised for Angelman syndrome research. Matthew Gocker’s comedy fundraiser brought the community together to support Payslie, her family, and FAST’s mission.
A high sensitivity assay of UBE3A ubiquitin ligase activity from Dr. Albert Keung’s Lab
A FAST-funded UBE3A activity assay from Dr. Albert Keung’s lab offers a faster, more sensitive tool for measuring and monitoring UBE3A function in Angelman syndrome research.
FAST Italy Hosts Its First Scientific Symposium on Angelman Syndrome
FAST Italy’s first-ever Scientific Symposium drew over 100 attendees and unveiled two new biotech companies, MavriX Bio and CourageAS Bio, advancing gene therapies for Angelman syndrome.
FAST Poland Organized the 1st Polish National Angelman Syndrome Conference
FAST Poland hosted its first National Angelman Syndrome Conference for International Angelman Day, drawing 164 registered guests to explore clinical research, epilepsy, safety, and quality of life for AS families.
International Angelman Day 2025: Round-Up
The global Angelman syndrome community celebrated International Angelman Day through blue illuminations, educational presentations, school activities, and outreach campaigns to raise awareness.
Introducing the Angelman Syndrome Global Community Advisory Board (CAB)
The Angelman Syndrome Alliance introduces its Global Community Advisory Board (CAB), a EURORDIS-trained group of parent advocates from around the world dedicated to representing family voices in Angelman syndrome research, policy, and advocacy.
2025 AS Congressional Advocacy Day: Legislative Priorities
Ahead of the second Angelman Syndrome Advocacy Day, FAST and ASF outline key 2025 priorities: protecting NIH research funding, safeguarding Medicaid, and supporting caregiver legislation.
FAST announces the launch of two biotech companies to advance investigational gene-targeted therapies for Angelman syndrome
FAST launches MavriX Bio and CourageAS Bio, two new biotech companies advancing gene replacement and gene-editing therapies for Angelman syndrome under its AS²Bio accelerator.